Tags : Result

Novartis Presents Results of Iptacopan (LNP023) in P-ll Study for

Shots: The P-II study involves assessing the efficacy, safety and PK of Iptacopan (LNP023) in patients with C3G (Cohort A) and patients who have undergone a kidney transplant and have C3G recurrence (Cohort B), interim results presented at ASN 2020 Result: @12wks., reduction in proteinuria (49%) as measured by 24hrs. UPCR assessment; improvement in plasma […]Read More

ViiV Healthcare Present Results of Long-Acting Cabotegravir and Rilpivirine at

Shots: The company reported the positive findings of a pooled analysis of six ongoing clinical studies which includes P-IIb/IIIb LATTE-2, ATLAS, ATLAS-2M, FLAIR, POLAR, and CUSTOMIZE studies evaluating long-acting cabotegravir and rilpivirine regimen in 1,744 patients with HIV-1 infection across 16 countries The positive findings showed 93% of participants maintained their injection visits amid the […]Read More

Janssen Reports Results of Tremfya (guselkumab) in Interim Analysis of

Shots: The P-II GALAXI 1 study involves assessing of Tremfya vs PBO in patients with mod. to severely active CD with intolerance to conventional therapies. In interim analyses, patients were randomized equally into 5 arms, with Tremfya (200/600/1200 mg (IV) @0, 4 & 8wks. respectively or with ustekinumab, dosed at ~6mg/kg (IV) @0wk. and dosed […]Read More

Amgen Report Five Year Data of Aimovig (erenumab-aooe) in Open-Label

Shots:   The OLE P-II study involves assessing of Aimovig monthly (70mg) vs PBO in 383 eligible adult patients with an episodic migraine for 12wks. 250 patients increasing their dosage to 140mg monthly after a protocol amendment to assess the long-term safety of the higher dose The results of the OLE study showed the therapy helped […]Read More

Bayer Report Result of Nubeqa (darolutamide) + ADT in P-III

Shots: The P-III ARAMIS study involves assessing of Nubeqa (600mg, bid) + ADT vs PBO + ADT in 1,509 patients in a ratio (2:1) with nmCRPC who were receiving a concomitant GnRH analog or had a bilateral orchiectomy The P-III ARAMIS study resulted in meeting its 1EPs i.e, improvement in MFS (40.4 vs 18.4mos.) Nubeqa […]Read More

AstraZeneca and Daiichi Sankyo Report Result of Trastuzumab Deruxtecan in

Shots: The P-II DESTINY-Breast01 study involves assessing of trastuzumab deruxtecan in 184 patients with HER2+ unresectable/ mBC prior treated with trastuzumab emtansine across 100 sites globally The P-II DESTINY- Breast01 study results: ORR (60.9%); DCR (97.3%); mDOR (14.8mos.); mPFS (16.4 mos.); estimated OS @12mos. (86%); safety & tolerability profile is consistent with P-I study Trastuzumab […]Read More